Literature DB >> 11557735

Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats.

T M Seasholtz1, T Zhang, M R Morissette, A L Howes, A H Yang, J H Brown.   

Abstract

We have previously shown that the function of the small G protein Rho is required for vascular smooth muscle cell proliferation and migration. We hypothesized that changes in Rho or Rho signaling might contribute to enhanced vascular proliferative responses associated with hypertension. Western blot analysis revealed that total RhoA expression was approximately 2-fold higher in aortas, tail arteries, and aortic smooth muscle cells (ASMCs) obtained from adult male spontaneously hypertensive rats (SHR) compared with those from Wistar Kyoto rats (WKY). An increase in active GTP-bound RhoA was detected in aortic homogenates by affinity precipitation with the RhoA effector rhotekin and by examining RhoA-[(35)S]GTPgammaS binding. RhoA protein and activity were also increased in vessels from rats treated with N-nitro-L-arginine methyl ester to increase blood pressure. Thrombin-stimulated RhoA activation was also significantly greater in ASMCs from SHR. As a functional correlate of these changes in Rho signaling, thrombin-stimulated DNA synthesis was enhanced in tail arteries and ASMCs from SHR. Expression of the cyclin-dependent kinase inhibitor p27(Kip1) was decreased by two thirds in SHR, and this decrease was mimicked in ASMCs by expression of a constitutively active (GTPase-deficient) mutant of RhoA. Wortmannin (10 nmol/L) fully inhibited the decrease in p27(Kip1) induced by RhoA, and a membrane-targeted catalytic subunit of phosphatidylinositol-3 kinase (PI3K [p110(CAAX)]) decreased p27(Kip1) expression, suggesting that RhoA signals through PI3K. These data provide evidence that RhoA brings about changes in DNA synthesis through reduced expression of p27(Kip1), mediated in part via PI3K, and suggest that increases in RhoA expression and activity contribute to the enhanced vascular responsiveness observed in hypertension.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557735     DOI: 10.1161/hh1801.096337

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  29 in total

1.  Role of Rho kinase signalling in healthy and varicose human saphenous veins.

Authors:  Chrystelle Cario-Toumaniantz; Sandrine Evellin; Séverine Maury; Olivier Baron; Pierre Pacaud; Gervaise Loirand
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

Review 2.  The role of Rho protein signaling in hypertension.

Authors:  Gervaise Loirand; Pierre Pacaud
Journal:  Nat Rev Cardiol       Date:  2010-08-31       Impact factor: 32.419

Review 3.  Role of rho kinase in the functional and dysfunctional tonic smooth muscles.

Authors:  Márcio A F de Godoy; Satish Rattan
Journal:  Trends Pharmacol Sci       Date:  2011-04-15       Impact factor: 14.819

Review 4.  Involvement of Rho GTPases and their regulators in the pathogenesis of hypertension.

Authors:  Gervaise Loirand; Pierre Pacaud
Journal:  Small GTPases       Date:  2014-10-31

Review 5.  The COP9 signalosome and vascular function: intriguing possibilities?

Authors:  Douglas S Martin; Xuejun Wang
Journal:  Am J Cardiovasc Dis       Date:  2015-03-20

6.  Effect of aldosterone-producing adenoma on endothelial function and Rho-associated kinase activity in patients with primary aldosteronism.

Authors:  Takeshi Matsumoto; Kenji Oki; Masato Kajikawa; Ayumu Nakashima; Tatsuya Maruhashi; Yumiko Iwamoto; Akimichi Iwamoto; Nozomu Oda; Takayuki Hidaka; Yasuki Kihara; Nobuoki Kohno; Kazuaki Chayama; Chikara Goto; Yoshiki Aibara; Kensuke Noma; James K Liao; Yukihito Higashi
Journal:  Hypertension       Date:  2015-01-26       Impact factor: 10.190

Review 7.  StarD13: a potential star target for tumor therapeutics.

Authors:  Leila Jaafar; Zeinab Chamseddine; Mirvat El-Sibai
Journal:  Hum Cell       Date:  2020-04-09       Impact factor: 4.174

8.  Eplerenone improves endothelial function and arterial stiffness and inhibits Rho-associated kinase activity in patients with idiopathic hyperaldosteronism: a pilot study.

Authors:  Shinji Kishimoto; Kenji Oki; Tatsuya Maruhashi; Masato Kajikawa; Shogo Matsui; Haruki Hashimoto; Yuji Takaeko; Yasuki Kihara; Kazuaki Chayama; Chikara Goto; Yoshiki Aibara; Farina Mohamad Yusoff; Ayumu Nakashima; Kensuke Noma; James K Liao; Yukihito Higashi
Journal:  J Hypertens       Date:  2019-05       Impact factor: 4.844

9.  Phytoestrogen genistein protects against endothelial barrier dysfunction in vascular endothelial cells through PKA-mediated suppression of RhoA signaling.

Authors:  Zhenquan Jia; Wei Zhen; Pon Velayutham Anandh Babu; Dongmin Liu
Journal:  Endocrinology       Date:  2012-12-18       Impact factor: 4.736

10.  Y27632, a Rho-activated kinase inhibitor, normalizes dysregulation in alpha1-adrenergic receptor-induced contraction of Lyon hypertensive rat artery smooth muscle.

Authors:  Maria Regina Freitas; Masumi Eto; Jason A Kirkbride; Christa Schott; Jean Sassard; Jean-Claude Stoclet
Journal:  Fundam Clin Pharmacol       Date:  2009-03-09       Impact factor: 2.748

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.